Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor Fitzgerald
February 10, 2017 12:39 PM ESTCantor Fitzgerald analyst Elemer Piros doesn't have much nice to say about Intercept Pharmaceuticals (NASDAQ: ICPT) REGENERATE trial change. The firm maintained an Underweight rating and price target of $60.
The analyst does not see a change to their probability of success... More
Intercept Pharmaceuticals (ICPT) Trial Amendments 'Increase Probability for Success' - Wedbush
February 10, 2017 12:31 PM ESTWedbush analyst Liana Moussatos reiterated her Outperform rating and $224 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after protocol amendments to the Phase 3 REGENERATE trial, which she said er the bar for success, while retaining significant upside.
Moussatos commented, "Intercept announced two protocol amendments to... More
Intercept (ICPT) NASH Trial Updates Offers 'Positives and Negatives' - Baird
February 10, 2017 12:17 PM ESTBaird analyst Brian Skorney said today's REGENERATE amendments from Intercept Pharmaceuticals (NASDAQ: ICPT) offer 'Positives and Negatives', although he is Incrementally positive on the updates.
Skorney commented, "ICPT stock did 180 this morning after management scared investors by announcing a conference call to... More
Intercept Pharmaceuticals (ICPT) NASH Trial Changes Increase Probability of Success and Timely Approval - BMO
February 10, 2017 11:40 AM ESTBMO Capital analyst M. Ian Somaiya weighed in on Intercept Pharmaceuticals (NASDAQ: ICPT) made changes to its REGENERATE Phase III NASH trial. The changes, according to the analyst, increases the probability of success.
Somaiya commented, "We think it matters less... More
Intercept (ICPT) NASH Trial Changes Lowers the Hurdle for Success - FBR
February 10, 2017 11:35 AM ESTFBR Capital analyst Vernon Bernardino weighed in on Intercept Pharmaceuticals (NASDAQ: ICPT) after the company provided an update on its REGENERATE Phase III trial with obeticholic acid (OCA) in NASH patients with liver fibrosis.
"We think the study's changes reflect this view... More
UPDATE: Intercept Pharma (ICPT) Changes Main Goal in Phase Three Nash Study with OCA - Bloomberg
February 10, 2017 8:37 AM EST(Updated - February 10, 2017 8:41 AM EST)
Intercept Pharma (NASDAQ: ICPT) said that it made protocol changes to its phase three Nash study, according to Bloomberg, citing remarks from CEO Pruzanski on a conference call. Intercept changed its main goal to fibrosis... More
Intercept Pharma (ICPT) Falls 10% Ahead of Update on Phase 3 Trial of OCA
February 10, 2017 8:18 AM ESTIntercept Pharma (NASDAQ: ICPT) traded sharply lower after the company said it will provide an update on its Phase 3 REGENERATE trial of obeticholic acid (OCA) in NASH patients with liver fibrosis during a conference call today at 8:30 a.m. ET.
Shares traded... More
